

Budget Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/446,996
	Filing Date	December 30, 1999
	First Named Inventor	Johannes C. van Groeninghen
	Group Art Unit	1646
	Examiner Name	J. Andres
Sheet 2 of 7	Attorney Docket Number	2183.02-564911S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HE et al., 1986, Clinical Chemistry, Vol. 32, No. 6, pp. 1159, abstract #542.	
		HÖTTINK et al., Stability of Gonadorelin and Related Compounds, dissertation, U of Utrecht, 8/6/1998, CH-1; p. 15, para. 2.	
CB		LAUE et al., Amer. J. of Diseases of Children, 1985, vol. 139, no. 11, pp. 1097-1100.	
CB		LIMONTA et al., The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans, Front. Neuroendocrinol. 203, pp. 279-95, Vol. 24.	
CB		MORETTI et al., Locally Expressed LHRH Receptors Mediate the Oncostatic and Antimetastatic Activity of LHRH Agonists on Melanoma Cells, J. of Clin. Endocrin. & Metab., 2002, pp. 3791-97, Vol. 87, No. 8.	
CB		MORETTI et al., Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression, Endocrine-Related Cancer, 2003, pp. 161-67, Vol. 10, No. 2.	
CB		NECHUSHTAN et al., 1997 April 25, J. Biol. Chem., Vol. 272, No. 17, pp. 11597-603.	
		ROTE-LISTE, 1997.	
CB		VAN GROENINGHEN et al., Effects of luteinising-hormone-releasing hormone on nervous-system tumours, The Lancet, August 1, 1998, pp. 372-73, Vol. 352, No. 9125.	

Examiner Signature	<i>Christine Boerger</i>	Date Considered	1/10/2006
-----------------------	--------------------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.